BullFrog AI
  • Home
  • About
  • Our Technology
  • Our Solution
  • News/Press
  • Contact

News and Press

February 15, 2018

BullFrog AI Announces Strategic Partnership with The Lieber Institute for Brain Development to Improve Antipsychotic Drug Selection

Cutting-edge artificial intelligence platform to analyze antipsychotic drug use data from leading brain development institute to predict patient outcomes. WASHINGTON DC, and BALTIMORE, MD – Feb. 15th, 2018 ― BullFrog…

Continue Reading

For media inquiries, please contact:

Liz Thibodeau
Thibodeau Media Group
Liz@thibmedia.com

Recent Articles

  • BullFrog AI Signs Memorandum of Understanding with KBP Biosciences
  • BullFrog AI Announces New Chief Technology Officer
  • BullFrog AI Announces Strategic Partnership with The Lieber Institute for Brain Development to Improve Antipsychotic Drug Selection
  • Johns Hopkins Applied Physics Laboratory Licenses Big-Data Analysis Tool to BullFrog AI
  • BULLFROG AI LAUNCHES

Archives

  • August 2019
  • December 2018
  • February 2018
  • October 2017

About BullFrog AI

Using the bfLeapTM Artificial Intelligence platform, BullFrog AI specializes in helping pharmaceutical companies predict which patients will respond to therapies in development.

Contact

P.O. Box 336
Boyds, MD 20841

info@bullfrogai.com

Connect

© 2019 BullFrog AI. – Powered by DMVG Technology

    • Home
    • About
    • Our Technology
    • Our Solution
    • News/Press
    • Contact